Batavia Biosciences is expanding its headquarters and R&D capabilities in its Netherlands facility.
Batavia Biosciences announced the expansion of its headquarters and R&D capacity in its Netherlands facility on June 14, 2022. The 22,500-ft² expansion will increase R&D activities for viral vector-based product development, including Lentivirus, adeno-associated virus (AAV), adenovirus, and measles virus vectors. The expansion is expected to be finalized by June 2023.
“The new laboratory floor space for R&D and analytical capabilities will aid the development capacity for customer projects,” said Chris Yallop, chief scientific officer, Batavia Biosciences, in a company press release. “The increased allocation for R&D capacity better positions Batavia Biosciences to serve as pacemakers to the community and to continue to bring promising candidate biopharmaceuticals from bench to clinic.”
According to a company press release, the increased R&D infrastructure is intended to meet increased global development for vaccine development, including live-attenuated, whole killed, vectored, or subunit vaccines.
Source: Batavia Biosciences
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
2 Commerce Drive
Cranbury, NJ 08512